Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.

Bagheri N, Shiina M, Lauffenburger DA, Korn WM.

PLoS Comput Biol. 2011 Feb;7(2):e1001085. doi: 10.1371/journal.pcbi.1001085. Epub 2011 Feb 17.

2.

Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus.

Zurakowski R, Wodarz D.

J Theor Biol. 2007 Mar 7;245(1):1-8. Epub 2006 Oct 4.

3.

Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.

Anders M, Christian C, McMahon M, McCormick F, Korn WM.

Cancer Res. 2003 May 1;63(9):2088-95.

4.

E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.

Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK.

Clin Cancer Res. 2007 May 15;13(10):3043-50.

5.

Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression.

Lee CH, Kasala D, Na Y, Lee MS, Kim SW, Jeong JH, Yun CO.

Biomaterials. 2014 Jul;35(21):5505-16. doi: 10.1016/j.biomaterials.2014.03.060. Epub 2014 Apr 13.

PMID:
24731708
6.

Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.

Watanabe Y, Hashimoto Y, Kagawa S, Kawamura H, Nagai K, Tanaka N, Urata Y, Fujiwara T.

Cancer Gene Ther. 2012 Nov;19(11):767-72. doi: 10.1038/cgt.2012.57. Epub 2012 Sep 7.

PMID:
22956040
7.

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.

Guse K, Ranki T, Ala-Opas M, Bono P, Särkioja M, Rajecki M, Kanerva A, Hakkarainen T, Hemminki A.

Mol Cancer Ther. 2007 Oct;6(10):2728-36.

8.

Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.

Su BH, Shieh GS, Tseng YL, Shiau AL, Wu CL.

Oncotarget. 2015 Nov 10;6(35):38308-26. doi: 10.18632/oncotarget.5702.

9.

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.

Coughlan L, Vallath S, Gros A, Giménez-Alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M, Alemany R, Hart IR.

Hum Gene Ther. 2012 Sep;23(9):960-79. doi: 10.1089/hum.2011.218. Epub 2012 Aug 27.

PMID:
22708837
10.

The antitumor effects of oncolytic adenovirus H101 against lung cancer.

Lei J, Li QH, Yang JL, Liu F, Wang L, Xu WM, Zhao WX.

Int J Oncol. 2015 Aug;47(2):555-62. doi: 10.3892/ijo.2015.3045. Epub 2015 Jun 11.

PMID:
26081001
11.

Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development.

Lavilla-Alonso S, Bauer MM, Abo-Ramadan U, Ristimäki A, Halavaara J, Desmond RA, Wang D, Escutenaire S, Ahtiainen L, Saksela K, Tatlisumak T, Hemminki A, Pesonen S.

Cancer Gene Ther. 2012 Feb;19(2):126-34. doi: 10.1038/cgt.2011.76. Epub 2011 Nov 18.

PMID:
22095385
13.

Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer.

Ma J, Zhao J, Lu J, Jiang Y, Yang H, Li P, Zhao M, Liu K, Dong Z.

Int J Mol Med. 2012 Dec;30(6):1403-9. doi: 10.3892/ijmm.2012.1133. Epub 2012 Sep 19.

PMID:
22992863
14.

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.

Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A.

Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8.

15.

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.

Gene Ther. 2005 Sep;12(17):1333-46.

PMID:
15920462
16.

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M, McNeish IA.

Mol Oncol. 2015 Apr;9(4):791-805. doi: 10.1016/j.molonc.2014.12.007. Epub 2014 Dec 29.

17.

Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.

Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Särkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, Hemminki A.

Mol Cancer Ther. 2007 Feb;6(2):742-51.

18.

PED/PEA-15 modulates coxsackievirus-adenovirus receptor expression and adenoviral infectivity via ERK-mediated signals in glioma cells.

Botta G, Perruolo G, Libertini S, Cassese A, Abagnale A, Beguinot F, Formisano P, Portella G.

Hum Gene Ther. 2010 Sep;21(9):1067-76. doi: 10.1089/hum.2009.181.

PMID:
20406097
19.

Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.

Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T.

Exp Cell Res. 2006 Feb 1;312(3):256-65. Epub 2005 Dec 13.

PMID:
16356494
20.

Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N, Kubo S.

Cancer Sci. 2013 Nov;104(11):1433-9. doi: 10.1111/cas.12267. Epub 2013 Sep 23.

Supplemental Content

Support Center